Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injections vs. daily growth hormone injection for treating paediatric growth hormone deficiency in Ireland
نویسندگان
چکیده
OBJECTIVES Paediatric growth hormone deficiency (pGHD) manifests as failure associated with inadequate (GH) production. Daily injections of recombinant human GH (dGH) [somatropin] is the current standard care, which has been shown to be well tolerated and effective, but suboptimal adherence, leading reduced effectiveness. Somatrogon, a once-weekly injectable long-acting GH, demonstrated clinical non-inferiority significantly lower life interference (i.e., treatment burden) vs. somatropin in two Phase 3 studies. This work evaluated cost-effectiveness cost-utility somatrogon vs dGHs from an Irish payer perspective.METHODS A Markov model was developed for patients starting or at 3-12 years continuing up achievement near adult height (NAH), driven by trial-based velocity (HV) treatment-specific adherence. Patients could discontinue end Year 1 (4%). DGH adherence (95.3%-65% over duration) adherence-growth relationship were based on published evidence. Higher 4%, tapering time, consultation. Treatment costs, monitoring costs due different wastage types (device setting adherence) sourced local data. Health utilities injection frequency derived literature. Scenario analysis, deterministic probabilistic sensitivity analysis performed.RESULTS Somatrogon led 1.87-3.66 cm greater NAH gain 0.21-0.50 higher quality adjusted (QALYs) dGHs, across base case scenarios evaluated. cost savings €5,699 - €21,974 per gained (€197 €527), patient. cost-effective result consistent analyses conducted.CONCLUSION weekly estimated NAH, QALYs, overall than pGHD.
منابع مشابه
Once versus twice daily injections of growth hormone in children with idiopathic short stature.
The aim of this study was to compare the growth response of 22 short pre-pubertal children without growth hormone deficiency, treated with a single daily growth hormone injection (group A), to the growth response of 27 similar children, treated with the same daily dose divided into 2 subcutaneous injections per day (group B), for 1 y, in a randomized study. GH treatment significantly promoted g...
متن کاملGrowth hormone replacement therapy in adults with growth hormone deficiency; thrice weekly low dose administration.
Recent reports on growth hormone (GH) therapy have shown that GH has various beneficial effects in GH deficient adults. In most of these studies, GH was administered daily. Because GH is still expensive and has to be delivered by subcutaneous injection, we studied the 6-month therapeutic effects of thrice weekly GH injection therapy and compared it with daily therapy. Twenty eight adult patient...
متن کاملGuideline for using growth hormone in paediatric patients in South Africa: treatment of growth hormone deficiency and other growth disorders.
The Paediatric and Adolescent Endocrine and Diabetes Society of South Africa (PAEDS-SA) recommends, in line with other international groups, that growth hormone (GH) therapy be considered for children and adolescents with significantly short stature and poor growth velocity in the following instances: GH deficiency; Turner syndrome; Prader-Willi syndrome; small-for-gestational-age children with...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Medical Economics
سال: 2023
ISSN: ['1369-6998', '1941-837X']
DOI: https://doi.org/10.1080/13696998.2023.2228167